Monday, March 17, 2014
Tisch MS Research Center of New York is delighted to announce that it has received regulatory approval needed to commence our proposed phase I clinical trial of mesenchymal stem cell-derived neural progenitor cells for the treatment of progressive multiple sclerosis. Patient enrollment and the study will begin shortly.
Tisch MS Research Center of New York
521 West 57th Street
4th Floor
New York, NY 10019
(646) 557-3900
Support Tisch MS
Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.